

## Monoclonal antibodies and immune checkpoint inhibitors

### Performance criteria and national standards

Performance criteria	National standard
<b>Performs</b> appropriate hand hygiene as per national guidelines, <b>identifies</b> appropriate PPE and provides <b>rationale</b> for use, throughout all interactions with patient	NS 3: Preventing and Managing Health Care Associated Infections
<b>Identifies patient</b> using appropriate unique identifiers at all relevant times for correct identification and procedure matching	NS 6: Communicating for safety
<b>Practices</b> within professional boundaries, role description, policies and procedures and standards of care—seeks advice when necessary	NS 1: Clinical Governance
<b>Adheres</b> to relevant local policies and guidelines, and uses facility approved resources for own and patient educational needs regarding administration of intended treatment	NS 1: Clinical Governance
<b>Discusses</b> the risks involved in the administration of MABs, and the precautions required— <b>identifies</b> any hazardous or cytotoxic exposure risk to self when administering	NS 4: Medication Safety
<b>Identifies</b> the class and target of the MAB and <b>discusses</b> how this may impact patient assessment and education	NS 4: Medication Safety
<b>Identifies</b> signs, symptoms and risk factors for infusion-related reactions including hypersensitivity reaction and cytokine release syndrome, prophylaxis and appropriate management strategies	NS 4: Medication Safety NS 8: Recognising and Responding to Acute Deterioration
<b>Demonstrates</b> knowledge of and <b>ability</b> to access monoclonal antibody treatment protocols (eviQ/local health facility/clinical trial)	
<b>Performs</b> pre-administration checks including: <ul style="list-style-type: none"> <li>• legal order</li> <li>• valid consent</li> <li>• allergies</li> <li>• fertility and pregnancy status (or planning)</li> <li>• pathology</li> <li>• medical imaging</li> <li>• appropriate vascular access</li> <li>• pre-medication and supportive treatments</li> <li>• adjuvant treatment.</li> </ul>	NS 2: Partnering with Consumers NS 3: Preventing and Managing Health Care Associated Infections NS 4: Medication Safety NS 5: Comprehensive Care NS 6: Communicating for Safety
<b>Escalates</b> variances and concerns effectively, or discusses when and how variances may need to be escalated	NS 8: Recognising and Responding to Acute Deterioration
<b>Provides</b> age-appropriate education to patient/carer/family member, maintaining universal health literacy standards and specific to treatment and disease. Checks understanding and provides opportunity to patient/carer/family to ask questions	NS 2: Partnering with Consumers NS 4: Medication Safety NS 6: Communicating for Safety
<b>Performs</b> comprehensive patient assessment relevant to treatment modality, disease, adjuvant treatment and is relevant to patient's developmental status/cognition/language/age	NS 2: Partnering with Consumers NS 4: Medication Safety NS 5: Comprehensive Care NS 6: Communicating for Safety NS 8: Recognising and Responding to Acute Deterioration

## Monoclonal antibodies and immune checkpoint inhibitors Performance criteria and national standards

Performance criteria	National standard
<b>Identifies</b> potential side effects of intended treatment and demonstrates understanding of accurate grading and escalation processes.	NS 4: Medication Safety NS 5: Comprehensive Care NS 6: Communicating for Safety NS 8: Recognising and Responding to Acute Deterioration
<b>Ensures</b> patient (parent or legal guardian if patient unable) has provided consent for administration by staff undertaking supervised practice or competency assessment	NS 2: Partnering with Consumers NS 4: Medication Safety NS 6: Communicating for Safety
<b>Gathers</b> equipment and <b>prepares</b> set-up area in safe, cohesive manner	NS 3: Preventing and Managing Health Care Associated Infections NS 4: Medication Safety
<b>Leads</b> the checking procedure including the rights of medication administration, as per national and local guidelines	NS 4: Medication Safety
<b>Demonstrates</b> effective communication with the patient throughout the procedure	NS 2: Partnering with Consumers NS 5: Comprehensive Care NS 6: Communicating for Safety
<b>Demonstrates</b> correct technical procedure for administering intravenous MABs, including order of PPE, hand hygiene, IV connections, infusion pump settings, line labelling	NS 3: Preventing and Managing Health Care Associated Infections NS 4: Medication Safety
<b>Monitors</b> patient throughout infusion, and ensures post-infusion monitoring as per recommendations for MAB/s administered, and provides effective clinical handover where indicated	NS 4: Medication Safety NS 5: Comprehensive Care NS 6: Communicating for Safety NS 8: Recognising and Responding to Acute Deterioration
<b>Demonstrates</b> correct technical procedure for flushing line (or not flushing line) at end of infusion and disconnecting	NS 4: Medication Safety
<b>Demonstrates</b> correct disposal of all equipment	NS 3: Preventing and Managing Health Care Associated Infections
<b>Documents</b> assessment, variations, escalation and outcome (where indicated), provision of education and procedure in medical records as required by local policies and guidelines	NS 4: Medication Safety NS 5: Comprehensive Care NS 6: Communicating for Safety NS 8: Recognising and Responding to Acute Deterioration